Studies on quinazolinones as dual inhibitors of Pgp and MRP1 in multidrug resistance.

Bioorg Med Chem Lett

Department of Medicinal Chemistry, Xenova Ltd., 957 Buckingham Avenue, Slough, Berkshire SL1 4NL, UK.

Published: February 2002

AI Article Synopsis

Article Abstract

The syntheses and SAR studies of various quinazolinone compounds are described for the dual inhibition of Pgp and MRP1 in multidrug resistance.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(01)00804-6DOI Listing

Publication Analysis

Top Keywords

pgp mrp1
8
mrp1 multidrug
8
multidrug resistance
8
studies quinazolinones
4
quinazolinones dual
4
dual inhibitors
4
inhibitors pgp
4
resistance syntheses
4
syntheses sar
4
sar studies
4

Similar Publications

Protein abundance of drug transporters and drug-metabolizing enzymes in paired healthy and tumor tissue from colorectal cancer patients.

Int J Pharm

January 2025

Drug Delivery and Disposition, KU Leuven, Gasthuisberg ON2, Herestraat 49 - box 921, 3000 Leuven, Belgium. Electronic address:

The widespread prevalence of colorectal cancer and its high mortality rate emphasize the urgent need for more effective therapies. When developing new drug products, a key aspect is ensuring that sufficiently high concentrations of the active drug are reached at the site of action. Drug transporters and drug-metabolizing enzymes can significantly influence the absorption and local accumulation of drugs in intestinal tissue.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to explore how asiatic acid (AA) affects the drug resistance in human leukemia cells (K562/ADR) resistant to adriamycin (ADR).
  • AA was found to reduce the resistance of these cells and enhance the effectiveness of ADR, as shown by various assays including CCK-8 and flow cytometry.
  • The results indicated that AA down-regulates the expression of certain proteins related to drug resistance, suggesting a potential mechanism for reversing resistance in these cancer cells.
View Article and Find Full Text PDF

Breast cancer is one of the most common cancers among women. Nowadays postoperative adjuvant chemotherapy is the mainstay for clinical treatment of breast cancer. However, the emergence of multidrug resistance (MDR) in breast cancer has become a main reason for the failure of clinical chemotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • - The study highlights the challenge of multi-drug resistance (MDR) in cancer treatment, mainly due to the overexpression of ABC transporters like P-glycoprotein (P-gp), which affects the effectiveness of chemotherapy drugs.
  • - Researchers explored the biaryl amide skeleton for potential agents to reverse MDR and identified a compound, D2, that significantly reversed resistance to drugs like paclitaxel and cisplatin in various cancer cell lines.
  • - Compound D2 works by binding to P-gp, lowering its expression, and enhancing drug accumulation in cells, showing promise as a solution to combat MDR in cancer treatments.
View Article and Find Full Text PDF

Drug efflux transporters, especially those belonging to the ATP-binding cassette (ABC) transporter superfamily, play a crucial role in various drug resistance issues, including multidrug resistance (MDR) in cancer and treatment-resistant depression (TRD) in individuals with major depressive disorder. Key transporters in this context include P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), and breast cancer resistance protein (BCRP). This study aimed to investigate the modulatory effects of polyoxyethylene (20) sorbitan monolaurate (Tween 20) on these efflux transporters and to evaluate its potential for overcoming drug resistance in two models: an cancer MDR model and an TRD model.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!